Immunovant, Inc. Common Stock (IMVT) is a publicly traded Healthcare sector company. As of May 20, 2026, IMVT trades at $35.27 with a market cap of $5.40B and a P/E ratio of -9.53. IMVT moved +31.65% today. Year to date, IMVT is +1.47%; over the trailing twelve months it is +78.84%. Its 52-week range spans $12.72 to $32.10. Analyst consensus is strong buy with an average price target of $44.88. Rallies surfaces IMVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IMVT-1402 Shows 72.7% ACR20 Response in D2T RA; $902M Cash Runway: IMVT-1402 achieved ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8% at Week 16 in 165 evaluable difficult-to-treat rheumatoid arthritis patients. Immunovant held $902.1 million in cash as of March 31, 2026, supporting development through a potential Graves’ disease launch and H2 2026 trial updates.
| Metric | Value |
|---|---|
| Price | $35.27 |
| Market Cap | $5.40B |
| P/E Ratio | -9.53 |
| EPS | $-2.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.10 |
| 52-Week Low | $12.72 |
| Volume | 9.31M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-413.84M |
| Gross Margin | 0.00% |
8 analysts cover IMVT: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.88.